首页> 外文OA文献 >Two Distinct Amyloid β-Protein (Aβ) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses*
【2h】

Two Distinct Amyloid β-Protein (Aβ) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses*

机译:两种截然不同的淀粉样蛋白(Aβ)组装途径,可通过荧光相关光谱法,形态学和毒性分析鉴定出低聚物和原纤维

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nonfibrillar assemblies of amyloid β-protein (Aβ) are considered to play primary roles in Alzheimer disease (AD). Elucidating the assembly pathways of these specific aggregates is essential for understanding disease pathogenesis and developing knowledge-based therapies. However, these assemblies cannot be monitored in vivo, and there has been no reliable in vitro monitoring method at low protein concentration. We have developed a highly sensitive in vitro monitoring method using fluorescence correlation spectroscopy (FCS) combined with transmission electron microscopy (TEM) and toxicity assays. Using Aβ labeled at the N terminus or Lys16, we uncovered two distinct assembly pathways. One leads to highly toxic 10–15-nm spherical Aβ assemblies, termed amylospheroids (ASPDs). The other leads to fibrils. The first step in ASPD formation is trimerization. ASPDs of ∼330 kDa in mass form from these trimers after 5 h of slow rotation. Up to at least 24 h, ASPDs remain the dominant structures in assembly reactions. Neurotoxicity studies reveal that the most toxic ASPDs are ∼128 kDa (∼32-mers). In contrast, fibrillogenesis begins with dimer formation and then proceeds to formation of 15–40-nm spherical intermediates, from which fibrils originate after 15 h. Unlike ASPD formation, the Lys16-labeled peptide disturbed fibril formation because the Aβ16–20 region is critical for this final step. These differences in the assembly pathways clearly indicated that ASPDs are not fibril precursors. The method we have developed should facilitate identifying Aβ assembly steps at which inhibition may be beneficial.
机译:淀粉样β蛋白(Aβ)的非原纤维组装体被认为在阿尔茨海默病(AD)中起主要作用。阐明这些特定聚集体的组装途径对于理解疾病的发病机制和开发基于知识的疗法至关重要。然而,这些组装体不能在体内进行监测,并且在低蛋白浓度下还没有可靠的体外监测方法。我们已经开发了一种高灵敏度的体外监测方法,该方法使用了荧光相关光谱(FCS)结合透射电子显微镜(TEM)和毒性试验。使用在N末端或Lys16标记的Aβ,我们发现了两个不同的组装途径。一种导致剧毒的10-15 nm球形Aβ组装体,称为淀粉样球体(ASPD)。另一个导致原纤维。 ASPD形成的第一步是三聚。缓慢旋转5小时后,来自这些三聚体的质量形式的ASPD约为330 kDa。在至少24小时内,ASPD仍是组装反应中的主要结构。神经毒性研究表明,毒性最大的ASPD为〜128 kDa(〜32-mers)。相反,原纤维形成始于二聚体形成,然后发展到15–40 nm球形中间体的形成,15 h后从中产生原纤维。与ASPD形成不同,Lys16标记的肽干扰了原纤维的形成,因为Aβ16-20区域对于这一最后步骤至关重要。组装途径中的这些差异清楚地表明ASPD不是原纤维前体。我们开发的方法应有助于识别抑制作用可能有益的Aβ组装步骤。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号